Innate Pharma SA (IPHA) is a globally leading biotechnology company focused on discovering, developing, and commercializing highly differentiated, high potential first-in-class immunotherapy drugs to enhance the immune system's ability to recognize and attack cancer cells. Founded in 1999 and based in Marseille, France, Innate Pharma has become a significant player in the field of immunotherapy, harnessing the power of the body's immune system to treat cancer.
The company specializes in drug development for various types of cancers, with an emphasis on harnessing the innate immune system, our first line of defense against cancer and other diseases. Over the years, it has built a rich and diverse portfolio of clinical-stage product candidates and preclinical compounds focused on monoclonal antibodies targeting receptors and pathways controlling the activation of the immune system. These include both proprietary and partnered assets.
Innate Pharma has managed to establish strategic alliances with top-tier pharmaceutical and biotechnology companies. One of its notable collaborations is the one shared with AstraZeneca and its global biologics research and development arm, MedImmune. Through these partnerships, Innate Pharma has been able to leverage its expertise in antibody discovery and development. Further, it has been able to co-develop and commercialize current and future therapeutic candidates in oncological indications, boosting its global footprint.
Another significant aspect of Innate Pharma's operation is research and innovation. The company is actively involved in novel technological acquisitions and respects the principles of the 3Rs (Replacement, Reduction, and Refinement) when conducting its various research activities. It also has a proprietary technology platform that is geared toward the discovery of new therapeutic antibodies.
Innate Pharma’s strategic approach to oncology research and therapeutics has put it at the forefront of immuno-oncology. Its leading clinical-stage product, monalizumab, has shown a high promise as it progresses through late-stage clinical trials. It also has various other promising candidates in pipeline focusing on treating various forms of cancer, reflecting the company’s commitment to science and the needs of patients.
In conclusion, Innate Pharma is at the forefront of medical innovation, delivering on the potential of immuno-oncology through scientifically-grounded research, strategic collaborations with industry leaders, and a strong dedication to improving patient outcomes in the ever-evolving fight against cancer. Its unique focus on the innate immunity, coupled with its extensive pipeline, has set Innate Pharma apart as a leader in the field of immunotherapy. Stockholders view the organization as a promising investment due to its scientific expertise, business acumen, and strategic alliances.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Innate Pharma (IPHA) has secured funding through Q1 2028 after closing a partnership deal with Sobi, which includes a $75 million upfront payment and an additional €30 million from equity financing. This capital is intended to advance its clinical programs, particularly the confirmatory Phase 3 TELLOMAK-3 trial, which is set to begin patient enrollment in early 2027. While the deal provides a potential route to market and reduced spending has improved the financial outlook, the success largely hinges on efficient clinical execution and the performance of upcoming trial data for other programs.
Innate Pharma has extended its cash runway through Q1 2028 following a new strategic partnership with Sobi for lacutamab, which included a $75 million upfront payment. This deal advances lacutamab into a confirmatory Phase 3 study for T-cell lymphomas and provides Innate with significant potential milestone payments and royalties. Additionally, the company completed a €30 million equity financing and is progressing other key clinical programs, including IPH4502 and IPH5201, with several important readouts expected in late 2026 and early 2027.
Innate Pharma (IPHA) reported its Q2 2026 earnings, highlighting significant progress in its oncology pipeline, particularly with lacutamab and its proprietary antibody-drug conjugate (ADC) technology. The company secured capital through a partnership with Sobi and an equity offering, extending its operational runway into early 2028. Key catalysts include a Phase 3 readout for monalizumab and initial clinical data for its Nectin-4 ADC program, with accelerated approval filings anticipated for lacutamab in Sezary Syndrome in late 2027.
Innate Pharma SA announced it will host a conference call and webcast on Thursday, September 17, 2026, at 2:00 p.m. CEST / 8:00 a.m. EDT. The purpose of the call is to provide a business update for the first half of 2026. Key company executives, including the CEO, CMO, COO, and CFO, will participate in the event.
McDermott Will & Schulte advised Innate Pharma on its strategic partnership with Sobi to license lacutamab, an anti-KIR3DL2 antibody for T-cell lymphoma. This partnership is crucial for initiating the TELLOMAK-3 confirmatory phase 3 Study in cutaneous T cell lymphoma (CTCL), aiming for accelerated approval of lacutamab in Sezary syndrome. The McDermott team involved partners and associates specializing in Life Sciences/Transaction and Antitrust aspects.